Focusing on Risk Communication About Medicines: Why Now?

Por Bahri, Priya, Harrison-Woolrych, Mira
Publicado em 2012

Listen to the public and fulfil their information interests – translating vaccine communication research findings into guidance for regulators

Por Bahri, Priya, Castillon Melero, Mireia
Publicado no Br J Clin Pharmacol (2018)

Application of real-time global media monitoring and ‘derived questions’ for enhancing communication by regulatory bodies: the case of human papillomavirus vaccines

Por Bahri, Priya, Fogd, Julianna, Morales, Daniel, Kurz, Xavier
Publicado no BMC Med (2017)

Proposals for Engaging Patients and Healthcare Professionals in Risk Minimisation from an Analysis of Stakeholder Input to the EU Valproate Assessment Using the Novel Analysing Sta...

Por Bahri, Priya, Morales, Daniel R., Inoubli, Adrien, Dogné, Jean-Michel, Straus, Sabine M. J. M.
Publicado no Drug Saf (2020)

The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products

Por Smith, Meredith Y., Russell, Andrea, Bahri, Priya, Mol, Peter G. M., Frise, Sarah, Freeman, Emily, Morrato, Elaine H.
Publicado no Drug Saf (2017)

Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments

Por McGettigan, Patricia, Alonso Olmo, Carla, Plueschke, Kelly, Castillon, Mireia, Nogueras Zondag, Daniel, Bahri, Priya, Kurz, Xavier, Mol, Peter G. M.
Publicado no Drug Saf (2019)

Correction to: Patient Registries: An Underused Resource for Medicines Evaluation: Operational proposals for increasing the use of patient registries in regulatory assessments

Por McGettigan, Patricia, Alonso Olmo, Carla, Plueschke, Kelly, Castillon, Mireia, Nogueras Zondag, Daniel, Bahri, Priya, Kurz, Xavier, Mol, Peter G. M.
Publicado no Drug Saf (2019)